Evaluating the mosquitocidal potential of the isoxazoline sarolaner against the yellow fever mosquito, Aedes aegypti (Diptera: Culicidae)
Medical and Veterinary Entomology · 2026-12 · 40 (4) · 815-824
DOI: 10.1111/mve.12827 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical and Veterinary Entomology, online erschienen am 14.07.2025. Verfasst von Kendra A Dagg und 2 weiteren Autor:innen. Beteiligte Einrichtung: Entomology and Nematology Department, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Aedes, Insecticides, Azetidines, Isoxazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: United States Department of Defense, U.S. Department of Defense.
Abstract (Originalsprache)
Aedes aegypti Linnaeus 1762 (Diptera: Culicidae) is the primary vector of several pathogens of public health significance. Insecticide‐based preventative measures are a key component of vector‐borne disease control programmes. However, widespread insecticide resistance threatens the effectiveness of current control strategies. Sarolaner, an isoxazoline insecticide, offers a novel mode of action and is primarily used for controlling ticks, fleas and mites in companion animals. This study evaluates the insecticidal efficacy of sarolaner against both laboratory‐susceptible and resistant strains of Ae. aegypti through various exposure routes. In topical assays, sarolaner outperformed permethrin by >8‐fold and >21‐fold greater efficacy against resistant strains at 24 and 72 h, respectively. Conversely, it underperformed in susceptible strains by over 8‐fold and 2‐fold at the same time points. In larval assays, sarolaner exhibited >300‐fold greater toxicity than spinosad at 24 and 48 h for both susceptible and resistant strains. Blood‐feeding assays showed sarolaner was more toxic than ivermectin by over 17‐fold and 10‐fold in susceptible and resistant strains, respectively, up to 120 h. While sarolaner was less toxic than dinotefuran in resistant strains through sugar feeding, it was over 3‐fold more toxic in susceptible strains. Notably, no cross‐resistance was detected with dinotefuran or ivermectin through oral, sugar or blood‐feeding applications, though slight cross‐resistance was observed with permethrin and spinosad. This study highlights sarolaner's potential as an effective adulticide and larvicide against Ae. aegypti , supporting its further evaluation as a candidate for new chemical formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Entomology and Nematology Department, University of Florida, Gainesville, Florida, USA.
- USDA-ARS Center for Medical, Agricultural, and Veterinary Entomology, Gainesville, Florida, USA.
ORCID-Profile: Edwin R Burgess
Förderung
- United States Department of Defense
- U.S. Department of Defense
Zitieren
APA
Dagg, K. A., Estep, A. S., & Burgess, E. R. (2026). Evaluating the mosquitocidal potential of the isoxazoline sarolaner against the yellow fever mosquito, Aedes aegypti (Diptera: Culicidae). Medical and Veterinary Entomology, 40(4), 815-824. https://doi.org/10.1111/mve.12827
Vancouver
Dagg KA, Estep AS, Burgess ER. Evaluating the mosquitocidal potential of the isoxazoline sarolaner against the yellow fever mosquito, Aedes aegypti (Diptera: Culicidae). Medical and Veterinary Entomology. 2026;40(4):815-824. doi:10.1111/mve.12827
BibTeX
@article{Dagg2026,
author = {Dagg, Kendra A and Estep, Alden S and Burgess, Edwin R},
title = {Evaluating the mosquitocidal potential of the isoxazoline sarolaner against the yellow fever mosquito, Aedes aegypti (Diptera: Culicidae)},
journal = {Medical and Veterinary Entomology},
year = {2026},
volume = {40},
number = {4},
pages = {815--824},
doi = {10.1111/mve.12827}
}
EUVIMED